Drugs in the Pipeline
The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and immediately after discharge.
Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.
Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.
The Food and Drug Administration (FDA) has granted Fast Track designation to the investigational oral dual inhibitor, ASN002 (Asana BioSciences), for the treatment of moderate-to-severe atopic dermatitis.
The ERADICATE Hp2 trial enrolled 455 dyspepsia patients at 55 sites across the US and randomized them to receive 4 capsules, 3 times daily, of either Talicia or the active comparator (amoxicillin 250mg and omeprazole 10mg), for a period of 14 days.
In Study 303 (N=1375), rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, achieved statistical significance in 2 co-primary endpoints: pain freedom and freedom from most bothersome symptom (MBS).
In animal studies, the treatment was associated with improvement in both motor and cognitive function.
Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
The Company has completed a first in human study in healthy volunteers; a Phase 2 trial in adults with NASH is due to begin soon in the US.
The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of patients with osteoarthritis.
Primary sclerosing cholangitis (PSC) is a rare, chronic and progressive liver disorder that often occurs in the setting of inflammatory bowel disease.
To evaluate the safety and antiviral activity of the treatment, patients in the TOPAZ trial (N=292) were randomized to receive pimodivir 300mg or 600mg, pimodivir 600mg plus oseltamivir 75mg, or placebo twice daily for 5 days.
The vote was taken in a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee.
The NDA submission included data from two Phase 3 trials, SAMURAI and SPARTAN.
Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis
In EXPEDITION-8, 280 treatment-naïve HCV patients (genotypes 1, 2, 4, 5, and 6) with compensated cirrhosis were treated with Mavyret for 8-weeks; the primary efficacy measure was SVR12 rate.
Renal and Urology News Articles
- The Threat From Within: Most Breaches Due to Employee Errors
- Radical Prostatectomy Has Lasting Benefit for Localized Cancer
- Poor Vitamin K Status Linked to Low BMD, Increased Fracture Risk in ESRD
- Serum Phosphate at Dialysis Start Tied With Mortality
- Veterans Health Administration Hospitals Outperform Non-VHAs
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)